Revolution Medicines, Inc. (RVMD)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$445.8M
Cash & Equivalents
$354.2M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$32,527M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05462717 Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors PHASE1 Active Not Recruiting 222

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for RVMD.

SEC EDGAR Filings

All SEC filings for Revolution Medicines, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.